12 Health Care Stocks Moving In Thursday's Intraday Session
Portfolio Pulse from Benzinga Insights
In Thursday's intraday session, several healthcare stocks experienced significant movements. Societal CDMO and Enveric Biosciences saw substantial gains, while Kineta and Ironwood Pharmaceuticals faced notable declines. Revance Therapeutics and Castle Biosciences reported their Q4 earnings, influencing their stock performance.
February 29, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences' shares increased by 132.25% to $1.93, with a market value of $5.2 million.
The substantial gain in Enveric Biosciences' stock price could reflect positive investor sentiment or favorable news related to the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Revance Therapeutics' stock moved upwards by 29.68% to $7.34 after Q4 earnings, with a market cap of $644.5 million.
The positive movement in Revance Therapeutics' stock price likely results from favorable Q4 earnings, indicating strong financial performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
POSITIVE IMPACT
Societal CDMO's stock rose 132.6% to $1.07, with a market cap of $112.1 million.
The significant rise in stock price indicates strong investor confidence, potentially due to positive company developments or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Castle Biosciences' stock fell 20.85% to $19.3 after Q4 earnings, with a market value of $519.5 million.
The decline in Castle Biosciences' stock price post-Q4 earnings suggests the market's negative reaction to their financial results or outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
NEGATIVE IMPACT
Ironwood Pharmaceuticals' stock fell 39.89% to $9.09, with a market value of $1.4 billion.
The significant drop in Ironwood Pharmaceuticals' stock price could be due to adverse events or market reactions to their financial or operational updates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Kineta shares fell 42.5% to $1.3, with a market value of $13.5 million.
The sharp decline in Kineta's stock price suggests negative market sentiment or potentially disappointing company news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90